https://blueblood.com.tw/wp-content/uploads/2024/09/beautiful-transparent-water-drops-rain-water-soft-background-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302020-12-01 12:00:452025-06-27 09:36:32Completed trial production of protein at 500L mass production scale.
https://blueblood.com.tw/wp-content/uploads/2024/09/beautiful-transparent-water-drops-rain-water-soft-background-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302018-05-01 12:00:352025-06-27 09:46:07BB-101 Phase I clinical trial approved by the Ministry of Economic Affairs, receiving NT$15 million under the ‘A+ Enterprise Innovation R&D Program – Fast-Track Clinical Trial Review.’
https://blueblood.com.tw/wp-content/uploads/2024/09/dna-genetic-biotechnology-science-with-scientist-rsquo-s-hands-disruptive-technology-remix.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302018-04-01 12:00:302025-06-27 09:50:57NEGF (BB-101) received Taiwan FDA approval for clinical trials and began Phase I clinical trials at 3 medical centers in Taiwan.
https://blueblood.com.tw/wp-content/uploads/2024/09/3d-render-medical-background-with-dna-strands-connecting-dots-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302016-07-01 12:00:572025-06-27 09:55:59BB-101 passed Phase I clinical trials by the US FDA, eliminating risks of urinary flatworm infections during treatment.
https://blueblood.com.tw/wp-content/uploads/2024/09/dna-genetic-biotechnology-science-with-scientist-rsquo-s-hands-disruptive-technology-remix.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302016-06-01 12:00:082025-06-27 10:03:36Focused on developing drugs to promote wound healing for diabetic patients.
Completed trial production of protein at 500L mass production scale.
Completed cGMP 300L clinical active pharmaceutical ingredient production.
BB-101 Phase I clinical trial approved by the Ministry of Economic Affairs, receiving NT$15 million under the ‘A+ Enterprise Innovation R&D Program – Fast-Track Clinical Trial Review.’
NEGF (BB-101) received Taiwan FDA approval for clinical trials and began Phase I clinical trials at 3 medical centers in Taiwan.
BB-101 passed Phase I clinical trials by the US FDA, eliminating risks of urinary flatworm infections during treatment.
TVBS reported on Blue Blood Biotech’s ‘dissolvable needle trial’ for developing drugs targeting diabetic ulcers.
Focused on developing drugs to promote wound healing for diabetic patients.